| Dr Jeffrey M Berman, M/D/ | |
|
1095 Rydal Rd, Suite 100, Rydal, PA 19046-1711 | |
| (267) 620-1100 | |
| (215) 572-1279 |
| Full Name | Dr Jeffrey M Berman |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 31 Years |
| Location | 1095 Rydal Rd, Rydal, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861433922 | NPI | - | NPPES |
| 000451204 | Other | PA | AMERIHEALTH |
| 1143253 | Other | PA | KEYSTONE MERCY |
| 231937219 | Other | PA | TRICARE |
| 000451204 | Other | PW | HIGHMARK BLUE SHIELD |
| 0140618000 | Other | PA | KEYSTONE EAST |
| 14617 | Other | PA | HEALTH PARTNERS |
| 100012734 | Other | PA | PALMETTO GBA |
| 017720580003 | Medicaid | PA | |
| 231937219 | Other | PA | MULTIPLAN |
| 1167811002 | Other | PA | CIGNA |
| 231937219 | Other | PA | DEVON |
| 5234726 | Other | PA | AETNA |
| P2784785 | Other | PA | OXFORD |
| 000451204 | Other | PA | PERSONAL CHOICE |
| 231937219 | Other | PA | FIRST HEALTH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | MD062570L (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Abington Memorial Hospital | Abington, PA | Hospital |
| Holy Redeemer Hospital And Medical Center | Meadowbrook, PA | Hospital |
| Abington Health Lansdale Hospital | Lansdale, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Methodist Associates In Healthcare, Inc | 6406755651 | 264 |
| Amh Medical Staff Service Fund | 9830003813 | 42 |
News Archive
Today, Highmark Inc. closed its merger with Blue Cross of Northeastern Pennsylvania (BCNEPA) after securing approval from the Pennsylvania Insurance Department. The merged company will operate as Highmark Blue Cross Blue Shield and continue to provide health insurance coverage and administrative services to nearly 550,000 individuals in the 13 counties of northeastern Pennsylvania.
Bacterial exposure has been identified as a potential environmental risk factor in developing coeliac disease, a hereditary autoimmune-like condition that affects about one in 70 Australians.
In many parts of the world, including Southeast Asia and sub-Saharan Africa, exposure to a fungal product called aflatoxin is believed to cause up to 80 percent of liver cancer cases. This fungus is often found in corn, peanuts, and other crops that are dietary staples in those regions.
Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.
› Verified 3 days ago
| Entity Name | Amh Medical Staff Service Fund |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356384457 PECOS PAC ID: 9830003813 Enrollment ID: O20031114000011 |
News Archive
Today, Highmark Inc. closed its merger with Blue Cross of Northeastern Pennsylvania (BCNEPA) after securing approval from the Pennsylvania Insurance Department. The merged company will operate as Highmark Blue Cross Blue Shield and continue to provide health insurance coverage and administrative services to nearly 550,000 individuals in the 13 counties of northeastern Pennsylvania.
Bacterial exposure has been identified as a potential environmental risk factor in developing coeliac disease, a hereditary autoimmune-like condition that affects about one in 70 Australians.
In many parts of the world, including Southeast Asia and sub-Saharan Africa, exposure to a fungal product called aflatoxin is believed to cause up to 80 percent of liver cancer cases. This fungus is often found in corn, peanuts, and other crops that are dietary staples in those regions.
Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.
› Verified 3 days ago
| Entity Name | Methodist Associates In Healthcare, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053355131 PECOS PAC ID: 6406755651 Enrollment ID: O20040402000835 |
News Archive
Today, Highmark Inc. closed its merger with Blue Cross of Northeastern Pennsylvania (BCNEPA) after securing approval from the Pennsylvania Insurance Department. The merged company will operate as Highmark Blue Cross Blue Shield and continue to provide health insurance coverage and administrative services to nearly 550,000 individuals in the 13 counties of northeastern Pennsylvania.
Bacterial exposure has been identified as a potential environmental risk factor in developing coeliac disease, a hereditary autoimmune-like condition that affects about one in 70 Australians.
In many parts of the world, including Southeast Asia and sub-Saharan Africa, exposure to a fungal product called aflatoxin is believed to cause up to 80 percent of liver cancer cases. This fungus is often found in corn, peanuts, and other crops that are dietary staples in those regions.
Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jeffrey M Berman, M/D/ 1095 Rydal Rd, Suite 100, Rydal, PA 19046-1711 Ph: (267) 620-1100 | Dr Jeffrey M Berman, M/D/ 1095 Rydal Rd, Suite 100, Rydal, PA 19046-1711 Ph: (267) 620-1100 |
News Archive
Today, Highmark Inc. closed its merger with Blue Cross of Northeastern Pennsylvania (BCNEPA) after securing approval from the Pennsylvania Insurance Department. The merged company will operate as Highmark Blue Cross Blue Shield and continue to provide health insurance coverage and administrative services to nearly 550,000 individuals in the 13 counties of northeastern Pennsylvania.
Bacterial exposure has been identified as a potential environmental risk factor in developing coeliac disease, a hereditary autoimmune-like condition that affects about one in 70 Australians.
In many parts of the world, including Southeast Asia and sub-Saharan Africa, exposure to a fungal product called aflatoxin is believed to cause up to 80 percent of liver cancer cases. This fungus is often found in corn, peanuts, and other crops that are dietary staples in those regions.
Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy. Treatment with afatinib significantly reduced the risk of death by 19%, extending the survival of patients to a median of 7.9 months compared to 6.8 months on erlotinib.
› Verified 3 days ago
Dr. Charles I Wagner, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 1095 Rydal Rd, Suite 100, Rydal, PA 19046 Phone: 267-620-1100 Fax: 215-572-1279 | |
Dr. Stuart M Lubinski, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1095 Rydal Rd, Suite 100, Rydal, PA 19046 Phone: 267-620-1100 Fax: 215-572-1279 | |
Dr. Harvey Guttmann, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1095 Rydal Rd, Suite 100, Rydal, PA 19046 Phone: 267-620-1100 Fax: 215-572-1279 | |
Dr. Martin Chatzinoff, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1095 Rydal Rd, Suite 100, Rydal, PA 19046 Phone: 267-620-1100 Fax: 215-572-1279 | |
Dr. Cesar A Delatorre, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1095 Rydal Rd, Suite 100, Rydal, PA 19046 Phone: 267-620-1100 Fax: 215-572-1279 | |
Dr. Jonathan M Sternlieb, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 1095 Rydal Rd, Suite 100, Rydal, PA 19046 Phone: 267-620-1100 Fax: 215-572-1279 | |
Dr. Steven C Leskowitz, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1095 Rydal Rd, Suite 100, Rydal, PA 19046 Phone: 267-620-1100 Fax: 215-572-1279 |